A PHASE III PROSPECTIVE RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY WITH VINORELBINE AND CISPLATIN IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER WITH COMPANION TUMOUR MARKER EVALUATION.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Apr 2020 Biomarkers information updated
- 08 Nov 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 23 Nov 2009 Long-term results have been published in the Journal of Clinical Oncology.